Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1994-10-25
pubmed:abstractText
Formation of thiazolidine-2,4-dicarboxylic acid, the L-cysteine-glyoxylate adduct, is the putative mechanism by which L-cysteine reduces hepatic oxalate production from glycollate [Bais, Rofe and Conyers (1991) J. Urol. 145, 1302-1305]. This was investigated in isolated rat hepatocytes by the simultaneous measurement of both adduct and oxalate formation. Different diastereoisomeric ratios of cis- and trans-adduct were prepared and characterized to provide both standard material for the enzymic analysis of adduct in hepatocyte supernatants and to investigate the stability and configuration of the adduct under physiological conditions. In the absence of L-cysteine, hepatocytes produced oxalate from 2 mM glycollate at a rate of 822 +/- 42 nmol/30 min per 10(7) cells. The addition of L-cysteine to the incubation medium at 1.0, 2.5 and 5.0 mM lowered oxalate production by 14 +/- 2, 25 +/- 3 (P < 0.05) and 38 +/- 3% (P < 0.01) respectively. These reductions were accompanied by almost stoichiometric increases in the levels of the adduct: 162 +/- 6, 264 +/- 27 and 363 +/- 30 nmol/30 min per 10(7) cells. Adduct formation is therefore confirmed as the primary mechanism by which L-cysteine decreases oxalate production from glycollate. As urinary oxalate excretion is a prime risk factor in the formation of calcium oxalate stones, any reduction in endogenous oxalate production is of clinical significance in the prevention of this formation.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-1016264, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-1579049, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-1903459, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-2046830, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-2223823, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-2490775, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-2647367, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-2863924, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-444540, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-5073739, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-5569122, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-6060479, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-6151397, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-7049247, http://linkedlifedata.com/resource/pubmed/commentcorrection/7945199-911888
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0264-6021
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
302 ( Pt 3)
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
753-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Formation of the L-cysteine-glyoxylate adduct is the mechanism by which L-cysteine decreases oxalate production from glycollate in rat hepatocytes.
pubmed:affiliation
Division of Clinical Biochemistry, Institute of Medical and Veterinary Science, Adelaide, South Australia.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't